# A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

> **NCT06337032** · PHASE4 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 350 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** F/TAF (High Dose Tablet)
- **DRUG:** F/TAF (Low Dose Tablet)
- **DRUG:** F/TAF (Lowest Dose Tablet)
- **DRUG:** F/TAF (High Dose TOS)
- **DRUG:** F/TAF (Low Dose TOS)
- **DRUG:** F/TAF (Lowest Dose TOS)
- **DRUG:** E/C/F/TAF
- **DRUG:** E/C/F/TAF (Low Dose)
- **DRUG:** Cobicistat (High Dose)
- **DRUG:** Cobicistat (Low Dose)
- **DRUG:** Cobicistat (TOS)
- **DRUG:** B/F/TAF (High Dose)
- **DRUG:** B/F/TAF (Low Dose)
- **DRUG:** B/F/TAF (High Dose TOS)
- **DRUG:** B/F/TAF (Low Dose TOS)
- **DRUG:** B/F/TAF (Lowest Dose TOS)
- **DRUG:** 3rd ARV Agent
- **DRUG:** Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
- **DRUG:** ATV
- **DRUG:** DRV

## Key facts

- **NCT ID:** NCT06337032
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-27
- **Primary completion:** 2034-03
- **Final completion:** 2034-03
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06337032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06337032, "A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06337032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*